Galera Therapeutics (GRTX) Financials

$16.28

$16.24 (42,629.66%)

As on 20-Jul-2026 16:00EDT

Market cap

$3,382 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

0.1

P/B Ratio

27.1

Div. Yield

0 %

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	3.84	0.26	0.11	0.78
Gross Profit	--	--	-3.84	-0.26	-0.11	-0.78
Operating Expenses	5.73	6.04	14.15	46.69	51.23	73.37
Operating Profit (EBIT)	-5.73	-6.04	-20.16	-46.95	-51.23	-73.37
Other Income	--	--	--	--	0.51	--
Profit before Tax	149.04	149.05	-19.16	-59.08	-62.29	-80.53
Provision for Tax	--	--	-0.20	--	-0.07	7.19
Profit after Tax (Net Income)	149.04	149.05	-18.96	-59.08	-62.22	-87.73
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-62.22	-80.53

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Shareholder's Funds	5.02	6.55	-143.67	-131.19	-109.18	-58.00
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	152.10	152.37	139.84	128.38
Current Liabilities	1.14	0.65	1.67	4.96	13.38	12.94
Total Liabilities	1.14	7.20	10.10	26.14	44.04	83.31

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Non-Current Assets	0.10	0.10	0.10	4.51	5.50	5.92
Current Assets	6.06	7.10	10.00	21.63	38.54	77.39
Total Assets	7.31	--	10.10	26.14	44.04	83.31
Total Debt*	--	--	--	1.25	0.04	0.30
Net Current Assets	4.92	6.45	8.34	16.67	25.16	64.46

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Cash From Operating Activities	--	-6.05	-12.15	-44.85	-43.43	-67.96
Cash Flow from Investing Activities	--	--	--	--	23.99	5.24
Cash from Financing Activities	--	0.64	2.22	31.50	3.89	66.71
Net Cash Inflow / Outflow	--	--	--	--	-15.54	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Adjusted EPS ($)	--	--	-0.35	-1.09	-2.23	-3.32
Cash EPS ($)	--	--	-0.35	-1.09	-2.22	-3.29
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	-0.22	-0.82	-1.55	-2.57
Free Cash Flow per Share ($)	--	--	-0.22	-0.83	-1.56	-2.58

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
ROCE (%)	--	-217.40	13.86	49.43	74.59	343.69
ROE (%)	--	-217.40	13.79	49.16	74.43	338.16
ROA (%)	1,869.83	1,723.41	-104.61	-168.38	-97.72	-104.81
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	-12,321.19	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	--	--	--	8.35	30.15	-3.94
Net Profit Growth (%)	1,021.79	886.25	67.91	5.05	29.07	-18.20
EPS Growth (%)	--	--	0.68	0.51	0.33	-0.12
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Price / Earnings	0.14	--	--	-0.13	-0.67	-1.38
Price / Book Value	27.10	--	--	-0.06	-0.38	-2.09
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.70	--	--	0.20	-0.20	-0.70
Close Price ($)	--	--	--	0.15	1.49	4.59
High Price ($)	--	--	--	3.59	4.74	12.99
Low Price ($)	--	--	--	0.09	1.12	1.19
Market Cap ($ Cr)	3,382.31	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debt to Equity	--	--	--	-0.01	0.00	-0.01
Short term debt to equity ratio	--	--	--	0.00	0.00	-0.01
Current Ratio	5.31	11.00	6.00	4.36	2.88	5.98
Quick Ratio	5.31	--	--	--	--	--
Interest Coverage	--	--	--	-4.11	-4.43	-10.19

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	125.93	3,494.55	13,817.02	2,391.96
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Income Statement ($ Mln)